<DOC>
	<DOCNO>NCT00787995</DOCNO>
	<brief_summary>This multicenter , multinational , longitudinal study quantify endurance respiratory function subject diagnose MPS IVA well characterize spectrum symptom biochemical abnormality MPS IVA disease time .</brief_summary>
	<brief_title>A Clinical Assessment Study Subjects With Mucopolysaccharidosis IVA ( Morquio Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<mesh_term>Osteochondrodysplasias</mesh_term>
	<criteria>Willing able provide write , sign informed consent , case subject age &lt; 18 year , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . Documented history reduce GALNS activity relative normal range laboratory perform assay , document result molecular genetic test confirm diagnosis MPS IVA . Willing able comply study procedure . Use investigational product investigational medical device within 30 day prior screen . Previous hematopoietic stem cell transplant ( HSCT ) . Concurrent disease condition would interfere study participation pose safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Mucopolysaccharidosis IV type A</keyword>
	<keyword>MPS IV Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>galactose-6-sulfatase</keyword>
	<keyword>GALNS</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>ERT</keyword>
</DOC>